GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ligand Pharmaceuticals Inc (NAS:LGND) » Definitions » Operating Income

Ligand Pharmaceuticals (Ligand Pharmaceuticals) Operating Income

: $9.8 Mil (TTM As of Dec. 2023)
View and export this data going back to 1995. Start your Free Trial

Ligand Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-3.4 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $9.8 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Ligand Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-3.4 Mil. Ligand Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $28.1 Mil. Therefore, Ligand Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 was -11.95%.

Ligand Pharmaceuticals's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ligand Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 was -2.43%. Ligand Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 95.94%.


Ligand Pharmaceuticals Operating Income Historical Data

The historical data trend for Ligand Pharmaceuticals's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ligand Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.72 20.39 103.85 3.04 9.82

Ligand Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Income Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.10 14.21 -1.98 0.96 -3.36

Ligand Pharmaceuticals Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ligand Pharmaceuticals  (NAS:LGND) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ligand Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-13.432 * ( 1 - -6.38% )/( (567.921 + 607.316)/ 2 )
=-14.2889616/587.6185
=-2.43 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=769.226 - 10.803 - ( 190.502 - max(0, 15.727 - 253.994+190.502))
=567.921

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=787.216 - 9.591 - ( 170.309 - max(0, 16.782 - 237.429+170.309))
=607.316

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Ligand Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=68.912/( ( (25.979 + max(48.262, 0)) + (25.062 + max(44.353, 0)) )/ 2 )
=68.912/( ( 74.241 + 69.415 )/ 2 )
=68.912/71.828
=95.94 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(36.003 + 25.392 + 2.097) - (10.803 + 0.621 + 3.806)
=48.262

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(32.917 + 23.969 + 3.839) - (9.591 + 1.843 + 4.938)
=44.353

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Ligand Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-3.358/28.101
=-11.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Ligand Pharmaceuticals Operating Income Related Terms

Thank you for viewing the detailed overview of Ligand Pharmaceuticals's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Ligand Pharmaceuticals (Ligand Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA, USA, 92121
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Executives
Martine Zimmermann director C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BOULEVARD SUITE 110, SAN DIEGO CA 92121
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Andrew Reardon officer: CHIEF LEGAL OFFICER & C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Octavio Espinoza officer: Chief Financial Officer C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121
John W Kozarich director 10275 SCIENCE CENTER DR, SAN DIEGO CA 92121
Stephen L Sabba director DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791
John L Higgins officer: CEO & President 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jason Haas director C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Matthew W Foehr officer: EVP and COO 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
John L Lamattina director 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Jennifer R. Cochran director C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Charles S Berkman officer: Asso. Gen. Counsel, Secretary 11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037
Sunil Patel director 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282